Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.48 |
| ▸ | APAF1 | O14727 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.48 |
| ▸ | DRD1 | P21728 | 1/20 | 0.48 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3984108 | 1.00 | TDP1 (0.48) | TDP1HSD17B10APAF1CYP3A4CHRM2 | |
| SCHEMBL3984623 | 1.00 | TDP1 (0.48) | TDP1HSD17B10APAF1CYP3A4CHRM2 | |
| Hydrochloric Acid SCHEMBL8783045 | 0.97 | MEN1 (0.50) | TDP1HSD17B10APAF1CYP3A4CHRM2 | |
| SCHEMBL9641540 | 0.81 | ALOX5 (0.52) | KCNH2ACP3ALDH1A1 | |
| SCHEMBL283979 | 0.78 | SIGMAR1 (0.61) | HSD17B10APAF1CYP3A4CHRM2ADRA1A | |
| SCHEMBL28869351 | 0.78 | CYP3A4 (0.52) | HSD17B10APAF1CYP3A4CHRM2ADRA1A | |
| SCHEMBL30763462 | 0.78 | SIGMAR1 (0.61) | HSD17B10APAF1CYP3A4CHRM2ADRA1A | |
| SCHEMBL1200137 | 0.78 | SIGMAR1 (0.61) | HSD17B10APAF1CYP3A4CHRM2ADRA1A | |
| SCHEMBL8437895 | 0.78 | SIGMAR1 (0.61) | HSD17B10APAF1CYP3A4CHRM2ADRA1A | |
| SCHEMBL2390659 | 0.78 | CYP3A4 (0.52) | HSD17B10APAF1CYP3A4CHRM2ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103319374-B | Asymmetric synthetic method of (S)-rivastigmine | BIORTUS BIOSCIENCES CO LTD | 2015-04-22 | — | — | CN | claimed |
| CN-103319374-A | Asymmetric synthetic method of (S)-rivastigmine | WUXI BIORTUS BIOSCIENCES CO LTD | 2013-09-25 | — | — | CN | claimed |
| US-8084630-B2 | Process for the synthesis of ramelteon and its intermediates | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2011-12-27 | — | — | US | claimed |
| US-20090281176-A1 | PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-11-12 | — | — | US | claimed |
| EP-2098519-A1 | Process for the synthesis of ramelteon and its intermediates | Teva Pharmaceutical Industries Ltd. (IL) | 2009-09-09 | — | — | EP | claimed |
| US-20090069581-A1 | PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-03-12 | — | — | US | claimed |
| US-20040110729-A1 | Primary N-hydroxylamines | NIH | 2004-06-10 | — | — | US | claimed |
| CN-1419536-A | Process for the selective N-formylation of n-hydroxylamines | ABBOTT LAB (US) | 2003-05-21 | — | — | CN | claimed |
| US-6455589-B1 | AN ORALLY ADMINISTRABLE EFFECTIVE UNIT SOLID DOSAGE OF A PRIMARY N-HYDROXYLAMINE OR A SALT, FREE OF NITRONE; USEFUL FOR REDUCING OXIDATIVE DAMAGE OR DELAYING SENESCENCE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2002-09-24 | — | — | US | claimed |
| US-6048707-A | ANALYZING STRUCTURAL RELATIONSHIP BETWEEN MONOSACCHARIDES OF CARBOHYDRATE; DERIVATIZING CARBOHYDRATE, CONVERTING TO MONOSACCHARIDES, FORMING LABELED MONOSACCHARIDES, SEPARATING MONOSACCHARIDES BY ELECTROPHORESIS, DETECTING MONOSACCARIDES | GLYKO, INC. (US) | 2000-04-11 | — | — | US | claimed |
| EP-0635759-B1 | Method of photographic processing | KODAK LTD (GB) | 2000-03-15 | — | — | EP | claimed |
| US-5418117-A | Method of photographic processing | EASTMAN KODAK COMPANY (US) | 1995-05-23 | — | — | US | claimed |
| EP-0635759-A1 | Method of photographic processing | KODAK LIMITED (GB) | 1995-01-25 | — | — | EP | claimed |
| US-4797504-A | HYDROXYLAMINES AND PHENYLENEDIAMINE DERIVATIVES | BETZ LABORATORIES, INC. (US) | 1989-01-10 | — | — | US | claimed |
| EP-0266906-A2 | Method and composition for inhibiting acrylate ester polymerization | BETZ EUROPE, INC. (US) | 1988-05-11 | — | — | EP | claimed |
| US-4720566-A | Method and composition for inhibiting acrylonitrile polymerization | BETZ LABORATORIES, INC. (US) | 1988-01-19 | — | — | US | claimed |
| EP-0240297-A1 | Inhibiting polymerization of vinyl aromatic compounds | BETZ EUROPE, INC. (US) | 1987-10-07 | — | — | EP | claimed |
| US-20240294470-A1 | FRAGRANCE COMPOUNDS | GIVAUDAN SA (CH) | 2024-09-05 | — | — | US | disclosed |
| EP-0023663-B1 | METHOD FOR THE PREPARATION OF NEW HETEROCYCLES THAT CONTAIN OXYGEN | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1984-05-16 | — | — | EP | disclosed |
| EP-0023663-A2 | Method for the preparation of new heterocycles that contain oxygen | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1981-02-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281176-A1 | PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | CYP2B6, UGT1A6, CYP2A6 | TDP1 2994/4885HSD17B10 146/4885APAF1 4833/4885 |
| US-20240294470-A1 | FRAGRANCE COMPOUNDS | FASN, FAAH2, FADS2 | TDP1 4392/4885HSD17B10 35/4885APAF1 1593/4885 |
| US-20090069581-A1 | PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | CYP2B6, UGT1A6, CYP2A6 | TDP1 2771/4885HSD17B10 204/4885APAF1 4852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.